The next stage of our research concerned the level of anti-EBVCA and anti-EBNA antibodies (both IgA and IgG) in single EBV infection and EBV/JCV co-infection in relation to selected clinicopathological features such as risk group, Gleason score, and T stage. This evidence concerns the gene CD79A and Epstein-Barr virus infection.